{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.48","value":"6.5"},{"groupId":"OG001","spread":"1.26","value":"19.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"47"}],"units":"Participants"}],"description":"Tumor response was assessed as SD based on IMWG response criteria as not meeting criteria for CR, VGPR, PR, or progressive disease; PD as Increase of \\>=25% from lowest response level in any one or more of the following: serum M protein (absolute increase \\>=0.5 g/dl)c or urine M protein (absolute increase \\>=200 mg/24 h); or serum/urine M protein unmeasurable: difference between involved and uninvolved free light chain (FLC) levels; absolute increase \\>10 mg/dL; or % bone marrow plasma cells: absolute value \\>=10% or definite development of new bone lesions or soft tissue plasmocytomas or definite increase in the size of existing bone lesions or soft tissue plasmocytomas; or development of hypercalcemia attributed solely to the plasma cell proliferative disorder.","groups":[{"description":"bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles","id":"OG000","title":"Bortezomib"},{"description":"no treatment, observation only","id":"OG001","title":"Non-treated Control"}],"paramType":"NUMBER","populationDescription":"FAS included all the randomized subjects who were eligible for efficacy analysis, that is, excluding subjects who did not have baseline and/or post-baseline data. \"N\" (number of subjects analyzed) signifies the subjects evaluable this measure.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of study (approximately 4 years 7 months)","title":"Tumor Response: Percentage of Participants With Stable Disease (SD) or Progressive Disease (PD) Based on International Myeloma Working Group (IMWG) Response Criteria","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}